Top

Published in:

Open Access 01-10-2009 | Research

VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis

Authors: Peter Weber, Ping Wang, Stephane Maddens, Paul SH Wang, Rongqian Wu, Michael Miksa, Weifeng Dong, Michael Mortimore, Julian MC Golec, Peter Charlton

Published in: Critical Care | Issue 5/2009

Abstract

Introduction

Prevention of lymphocyte apoptosis by caspase inhibition has been proposed as a novel treatment approach in sepsis. However, it has not been clearly demonstrated that caspase inhibitors improve survival in sepsis models when dosed post-insult. Also, there are concerns that caspase inhibitors might suppress the immune response. Here we characterize VX-166, a broad caspase inhibitor, as a novel potential treatment for sepsis.

Methods

VX-166 was studied in a number of enzymatic and cellular assays. The compound was then tested in a murine model of endotoxic shock (lipopolysaccharide (LPS), 20 mg/kg IV) and a 10 d rat model of polymicrobial sepsis by caecal ligation and puncture (CLP).

Results

VX-166 showed potent anti-apoptotic activity in vitro and inhibited the release of interleukin (IL)-1beta and IL-18. In the LPS model, VX-166 administered 0, 4, 8 and 12 h post-LPS significantly improved survival in a dose-dependent fashion (P < 0.0028). In the CLP model, VX-166 continuously administered by mini-osmotic pump significantly improved survival when dosed 3 h after insult, (40% to 92%, P = 0.009). When dosed 8 h post-CLP, VX-166 improved survival from 40% to 66% (P = 0.19). Mode of action studies in the CLP model confirmed that VX-166 significantly inhibited thymic atrophy and lymphocyte apoptosis as determined by flow cytometry (P < 0.01). VX-166 reduced plasma endotoxin levels (P < 0.05), suggesting an improved clearance of bacteria from the bloodstream. Release of IL-1beta in vivo or T-cell activation in vitro were moderately affected.

Conclusions

Our studies enhance the case for the use of caspase inhibitors in sepsis. VX-166 itself has promise as a therapy for the treatment of sepsis in man.

Available only for authorised users

Awad SS: State-of-the-art therapy for severe sepsis and multisystem organ dysfunction. Am J Surg 2003, 186: 23S-30S. 10.1016/j.amjsurg.2003.10.004CrossRefPubMed

Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36: 296-327. 10.1097/01.CCM.0000298158.12101.41CrossRefPubMed

Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003, 112: 460-467.PubMedCentralCrossRefPubMed

Shimaoka M, Park EJ: Advances in understanding sepsis. Eur J Anaesthesiol Suppl 2008, 42: 146-153. 10.1017/S0265021507003389PubMedCentralCrossRefPubMed

Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6: 813-822. 10.1038/nri1943CrossRefPubMed

Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A: Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005, 78: 325-337. 10.1189/jlb.0105017CrossRefPubMed

Wang SD, Huang KJ, Lin YS, Lei HY: Sepsis-induced apoptosis of the thymocytes in mice. J Immunol 1994, 152: 5014-5021.PubMed

Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999, 27: 1230-1251. 10.1097/00003246-199907000-00002CrossRefPubMed

Chung CS, Wang W, Chaudry IH, Ayala A: Increased apoptosis in lamina propria B cells during polymicrobial sepsis is FasL but not endotoxin mediated. Am J Physiol Gastrointest Liver Physiol 2001, 280: G812-G818.PubMed

10.

Schroeder S, Lindemann C, Decker D, Klaschik S, Hering R, Putensen C, Hoeft A, von Ruecker A, Stüber F: Increased susceptibility to apoptosis in circulating lymphocytes of critically ill patients. Langenbecks Arch Surg 2001, 386: 42-46. 10.1007/s004230000181CrossRefPubMed

11.

Roth G, Moser B, Krenn C, Brunner M, Haisjackl M, Almer G, Gerlitz S, Wolner E, Boltz-Nitulescu G, Ankersmit HJ: Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem Biophys Res Commun 2003, 308: 840-846. 10.1016/S0006-291X(03)01482-7CrossRefPubMed

12.

Ayala A, Chung CS, Xu YX, Evans TA, Redmond KM, Chaudry IH: Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin. Immunology 1999, 97: 45-55. 10.1046/j.1365-2567.1999.00765.xPubMedCentralCrossRefPubMed

13.

Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166: 6952-6963.CrossRefPubMed

14.

Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, Cobb JP, Coopersmith C, Karl IE: Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002, 168: 2493-2500.CrossRefPubMed

15.

Bilbault P, Lavaux T, Lahlou A, Uring-Lambert B, Gaub MP, Ratomponirina C, Meyer N, Oudet P, Schneider F: Transient Bcl-2 gene down-expression in circulating mononuclear cells of severe sepsis patients who died despite appropriate intensive care. Intensive Care Med 2004, 30: 408-415. 10.1007/s00134-003-2118-zCrossRefPubMed

16.

Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drénou B: Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18: 487-494. 10.1097/00024382-200212000-00001CrossRefPubMed

17.

Guo RF, Huber-Lang M, Wang X, Sarma V, Padgaonkar VA, Craig RA, Riedemann NC, McClintock SD, Hlaing T, Shi MM, Ward PA: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000, 106: 1271-1280. 10.1172/JCI10793PubMedCentralCrossRefPubMed

18.

Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE: Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999, 162: 4148-4156.PubMed

19.

Iwata A, Stevenson VM, Minard A, Tasch M, Tupper J, Lagasse E, Weissman I, Harlan JM, Winn RK: Over-expression of Bcl-2 provides protection in septic mice by a trans effect. J Immunol 2003, 171: 3136-3141.CrossRefPubMed

20.

Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999, 96: 14541-14546. 10.1073/pnas.96.25.14541PubMedCentralCrossRefPubMed

21.

Salvesen GS, Riedl SJ: Caspase mechanisms. Adv Exp Med Biol 2008, 615: 13-23. full_textCrossRefPubMed

22.

Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174: 5110-5118.CrossRefPubMed

23.

Tinsley KW, Cheng SL, Buchman TG, Chang KC, Hui JJ, Swanson PE, Karl IE, Hotchkiss RS: Caspases -2, -3, -6, and -9, but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. Shock 2000, 13: 1-7. 10.1097/00024382-200013010-00001CrossRefPubMed

24.

Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1: 496-501. 10.1038/82741CrossRefPubMed

25.

Catalan MP, Esteban J, Subirá D, Egido J, Ortiz A: Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int 2003, 23: 123-126.PubMed

26.

Méthot N, Huang J, Coulombe N, Vaillancourt JP, Rasper D, Tam J, Han Y, Colucci J, Zamboni R, Xanthoudakis S, Toulmond S, Nicholson DW, Roy S: Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. J Exp Med 2004, 199: 199-207. 10.1084/jem.20031791PubMedCentralCrossRefPubMed

27.

Oberholzer C, Tschoeke SK, Moldawer LL, Oberholzer A: Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice. J Mol Med 2006, 84: 389-395. 10.1007/s00109-005-0017-1CrossRefPubMed

28.

Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ: Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002, 419: 395-399. 10.1038/nature01063CrossRefPubMed

29.

Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, Harding MW, Livingston DJ, Su MS: Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme. Science 1997, 275: 206-209. 10.1126/science.275.5297.206CrossRefPubMed

30.

Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP: Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005, 12: 255-269. 10.1159/000087104CrossRefPubMed

31.

Marshall JC: Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med 2000,26(Suppl 1):S75-S83. 10.1007/s001340051122CrossRefPubMed

32.

Scott AM, Saleh M: The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ 2007, 14: 23-31. 10.1038/sj.cdd.4402026CrossRefPubMed

33.

Wei Y, Fox T, Chambers SP, Sintchak J, Coll JT, Golec JM, Swenson L, Wilson KP, Charifson PS: The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem Biol 2000, 7: 423-432. 10.1016/S1074-5521(00)00123-XCrossRefPubMed

34.

Margolin N, Raybuck SA, Wilson KP, Chen W, Fox T, Gu Y, Livingston DJ: Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J Biol Chem 1997, 272: 7223-7228. 10.1074/jbc.272.11.7223CrossRefPubMed

35.

Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 1997, 272: 17907-17911. 10.1074/jbc.272.29.17907CrossRefPubMed

36.

Schotte P, Declercq W, Van HS, Vandenabeele P, Beyaert R: Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999, 442: 117-121. 10.1016/S0014-5793(98)01640-8CrossRefPubMed

37.

Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Brömme D, Puizdar V, Fonović M, Trstenjak-Prebanda M, Dolenc I, Turk V, Turk B: Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ 2003, 10: 881-888. 10.1038/sj.cdd.4401247CrossRefPubMed

38.

Matsuda N, Hattori Y: Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007, 43: 117-137. 10.1540/jsmr.43.117CrossRefPubMed

39.

Zhou M, Simms HH, Wang P: Adrenomedullin and adrenomedullin binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis. Ann Surg 2004, 240: 321-330. 10.1097/01.sla.0000133253.45591.5bPubMedCentralCrossRefPubMed

40.

Rittirsch D, Hoesel LM, Ward PA: The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007, 81: 137-143. 10.1189/jlb.0806542CrossRefPubMed

41.

Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH: The complex pattern of cytokines in sepsis: association between prostaglandins, cachectin and interleukins. Ann Surg 1991, 214: 141-148. 10.1097/00000658-199108000-00008PubMedCentralCrossRefPubMed

42.

Wang P, Ba ZF, Chaudry IH: Endothelium-dependent relaxation is depressed at the macro- and microcirculatory levels during sepsis. Am J Physiol 1995, 269: R988-R994.PubMed

43.

Yang S, Chung CS, Ayala A, Chaudry IH, Wang P: Differential alterations in cardiovascular responses during the progression of polymicrobial sepsis in the mouse. Shock 2002, 17: 55-60. 10.1097/00024382-200201000-00010CrossRefPubMed

44.

Grobmyer SR, Armstrong RC, Nicholson SC, Gabay C, Arend WP, Potter SH, Melchior M, Fritz LC, Nathan CF: Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol Med 1999, 5: 585-594.PubMedCentralPubMed

45.

Sarkar A, Hall MW, Exline M, Hart J, Knatz N, Gatson NT, Wewers MD: Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 2006, 174: 1003-1010. 10.1164/rccm.200604-546OCPubMedCentralCrossRefPubMed

46.

Conus S, Perozzo R, Reinheckel T, Peters C, Scapozza L, Yousefi S, Simon HU: Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med 2008, 205: 685-698. 10.1084/jem.20072152PubMedCentralCrossRefPubMed

47.

Kennedy NJ, Kataoka T, Tschopp J, Budd RC: Caspase activation is required for T cell proliferation. J Exp Med 1999, 190: 1891-1896. 10.1084/jem.190.12.1891PubMedCentralCrossRefPubMed

48.

Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007, 130: 918-931. 10.1016/j.cell.2007.07.009PubMedCentralCrossRefPubMed

49.

Yamada M, Ichikawa T, Ii M, Sunamoto M, Itoh K, Tamura N, Kitazaki T: Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J Med Chem 2005, 48: 7457-7467. 10.1021/jm050623tCrossRefPubMed

Title: VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis
Authors: Peter Weber
Ping Wang
Stephane Maddens
Paul SH Wang
Rongqian Wu
Michael Miksa
Weifeng Dong
Michael Mortimore
Julian MC Golec
Peter Charlton
Publication date: 01-10-2009
Publisher: BioMed Central
Published in: Critical Care / Issue 5/2009
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc8041

Keynote webinar | Spotlight on medication adherence

Springer Medicine

VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Effects of positive end-expiratory pressure on respiratory function and hemodynamics in patients with acute respiratory failure with and without intra-abdominal hypertension: a pilot study

Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

Clinical review: Goal-directed therapy in high risk surgical patients

Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review

Reflections on off hour admissions to ICU